TH
ALNY icon

Timber Hill’s Alnylam Pharmaceuticals ALNY Stock Holding History

Timber Hill’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,900
Closed -$559K – 960
2017
Q1 		$559K Buy
+10,900
New +$504K ﹤0.01% 1417
2016
Q2 		– Sell
-6,100
Closed -$383K – 2088
2016
Q1 		$383K Buy
6,100
+3,200
+110% +$213K ﹤0.01% 1678
2015
Q4 		$273K Sell
2,900
-7,500
-72% -$695K ﹤0.01% 1957
2015
Q3 		$836K Sell
10,400
-3,600
-26% -$400K ﹤0.01% 1513
2015
Q2 		$1.68M Buy
+14,000
New +$1.67M 0.01% 1177
2014
Q3 		– Sell
-9,500
Closed -$600K – 2550
2014
Q2 		$600K Sell
9,500
-20,500
-68% -$1.22M ﹤0.01% 1979
2014
Q1 		$2.01M Buy
+30,000
New +$2.32M 0.01% 1160
2013
Q3 		– Sell
-9,200
Closed -$285K – 3173
2013
Q2 		$285K Buy
+9,200
New +$245K ﹤0.01% 2830

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Timber Hill's ALNY Position: Q3 2014 in Review

Timber Hill sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2014, closing a stake of 4,542 shares — an estimated $287K sold.

Timber Hill first reported a position in ALNY in Q3 2013 and held it in 2 quarters. The position peaked at $338K in Q3 2013. 186 funds tracked by Wall St. Rank hold ALNY as of Q3 2014.

  • Timber Hill reported no remaining Alnylam Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Timber Hill sold 4,542 Alnylam Pharmaceuticals shares in Q3 2014, an estimated $287K.
  • Timber Hill first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Timber Hill's Alnylam Pharmaceuticals position peaked at $338K in Q3 2013.
  • 186 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2014.

Based on Timber Hill's 13F filing for Q3 2014, filed 24 Nov 2014.